KMS-12-BM
1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
KMS-12-BM cells are a human myeloma cell line derived from the bone marrow of a 64-year-old woman diagnosed with a non-producing type of multiple myeloma. They exhibit a chromosome marker, t(11;14)(q13;q32), indicating a translocation event involving chromosomes 11 and 14. These cells represent the plasmacytoid stage of B-cell differentiation. Notably, KMS-12-BM cells express CD20, CD38, and PCA-1. They do not produce surface or cytoplasmic immunoglobulins and lack the expression of Epstein-Barr virus nuclear antigen. To support their growth, KMS-12-BM cells can be cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, providing essential nutrients and factors for their survival and proliferation.
Why choose KMS-12-BM from AcceGen?
KMS-12-BM cells from AcceGen offer advantageous features for scientific research. They are sterile, negative for bacterial, fungal, and mycoplasma contamination, and undergo rigorous quality control. These cells demonstrate high viability and are prepared under standardized conditions by professional operators. These qualities ensure reliable and consistent results, making KMS-12-BM cells a valuable resource for studying multiple myeloma and plasma cell biology.
| Product Code | KMS 12 BM; KMS-12BM; KMS12-BM; KMS12BM; KMS-12; KMS12 |
| Species | Human |
| Cat.No | ABL-TC0346 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocyte-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Bone Marrow |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Myeloma Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
KMS-12-BM cells have emerged as a valuable tool in multiple myeloma and plasma cell biology research. These cells provide a robust model for investigating the intricacies of the disease, allowing researchers to delve into its underlying molecular mechanisms. Moreover, KMS-12-BM cells offer a platform to explore the proteome and identify potential cancer biomarkers that could aid in diagnosis and prognosis. They can also be utilized to analyze transcriptomic correlation, serving as a representative model for patient tumors and shedding light on the molecular factors influencing disease progression. Additionally, these cells play a pivotal role in drug screening studies, offering insights into drug sensitivity and supporting the prediction of therapeutic outcomes. Overall, KMS-12-BM cells contribute significantly to advancing our understanding of multiple myeloma and hold promise for improving patient care through personalized treatment strategies.
